Identifying Potential Drug Targets for Cardiovascular Disease through Proteomics

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, making it crucial to identify effective therapeutic targets. Recent advancements in genome-wide association studies (GWAS) offer insights into the genetic underpinnings of diseases, but translating these findings into actionable clinical strategies remains a challenge. This study leverages Mendelian randomisation (MR) to connect expressed proteins with CVD outcomes, providing a data-driven approach to identify potential drug targets. The researchers conducted a generalised summary-data-based MR (GSMR) analysis using isoform-specific protein groups from peripheral-blood mononuclear cells (PBMCs) and plasma protein measures from large cohorts, including Generation Scotland and the UK Biobank. They evaluated 5,114 protein isoforms in 736 individuals and identified five putative causal proteins linked to three CVD-related risk factors through GSMR analysis. Notably, 92 potential causal proteins were identified in the plasma analysis, with 59 supported by colocalisation, indicating a robust association between these proteins and CVD. The findings highlight the significance of protein measurement location and quantification methods in understanding CVD pathogenesis. One key protein, COMT, was consistently identified across both PBMC and plasma analyses, showing a significant association with Type II Diabetes and Essential Hypertension. This suggests that targeting COMT could be a promising strategy for managing these conditions and their cardiovascular implications. For individuals concerned about their metabolic health, understanding the role of these proteins can guide lifestyle and dietary choices. For instance, engaging in regular exercise and adopting a low-carb or ketogenic diet may help modulate the expression of these proteins, potentially reducing the risk of developing CVD. Monitoring biomarkers such as fasting insulin, triglycerides, and LDL cholesterol can provide insights into one's metabolic health and inform personalized health strategies. In summary, this study bridges the gap between genetic information and clinical application by identifying proteins that may serve as therapeutic targets for CVD. As research continues to evolve, staying informed about these developments can empower individuals to take proactive steps in managing their metabolic health and reducing the risk of cardiovascular disease.